On June 11, 2019 ONCURIOUS NV, a Belgium-based biotech company focusing on the development of innovative oncology treatments, reported that it has received from Flanders Innovation and Entrepreneurship (VLAIO) a project grant of close to €1 million to support the further pre-clinical development of its pipeline of next generation cancer immunotherapies (Press release, Oncurious, JUN 11, 2019, View Source [SID1234536999]). Oncurious will do this in close collaboration with VIB Discovery Sciences, steered by the scientific input of the VIB founding labs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This non-dilutive grant funding will be used to identify a number of multi-specific biologics with distinct modes of action against immunomodulatory targets. These candidates will then be assessed in pre-clinical tumor models, both as monotherapies and in combination with standard of care treatment. The funds will also support the further development of Oncurious, including the recruitment of several scientists.
Patrik De Haes, MD, Executive Chairman of ONCURIOUS NV comments, "We are delighted by the potential of our pipeline of next generation immunotherapies and this project grant will provide us with funding to generate and select the most appropriate candidates to take further into pre-clinical development. We believe that the development of our immunotherapy pipeline, will in time, be an important source of value for Oncurious’ shareholders."
Johan Cardoen, PhD, Managing Director of VIB comments, "We are pleased that VLAIO has recognized the compelling science behind our portfolio of next-generation immunotherapies for the treatment of cancer. This grant funding will enable Oncurious to hire scientists and conduct a range of experiments designed to provide the data needed to select the most appropriate novel immuno-oncology assets for further development."
– END –
For further information please contact:
Oxurion NV / Oncurious NV
Wouter Piepers
Global Head of Investor Relations & Communications
+32 16 75 13 10 / +32 478 33 56 32
[email protected]
VIB
Sooike Stoops
Expert Press and Public Communication
+32 9 244 66 11 / +32 474 28 92 52
[email protected]
EU – Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi
Tel: +44 20 7638 9571
[email protected] US – LifeSci Public Relations
Alison Chen
+1646-876-4932
[email protected]